AI Tools
qXR
qXR : prix, capacités, mises à jour et alternatives, lus sur les pages de l’éditeur.

En anglais
Key facts
- Price
- Not stated on the maker’s pages
- Free plan
- Not stated on the maker’s pages
- Platforms
- Web · API
- API
- Yes Read on documentation.qure.ai
- Open source
- Not stated on the maker’s pages
- Last update
- 17 Sept 2026 Read on qure.ai
Qure.ai’s qXR analyzes chest X-rays and provides pre-read findings across the lungs, pleura, mediastinum, bones, diaphragm and heart. It can generate AI overlays and pre-filled reports, and help teams sort unremarkable scans to manage reporting backlogs.
The product is aimed at hospitals, imaging centers, teleradiology teams and screening programs, including TB and lung-cancer screening. Qure.ai describes it as reporting assistance; prospects can request a demo. No price was available on the official pages accessed, so cost and any additional fees are unconfirmed.
- Category
- Data & Analytics
- Read from the maker’s pages
- 2026-11-18
Company
Features
- Analyzes chest X-rays for findings across multiple chest structures
- Provides AI overlays and pre-filled reports
- Helps segregate unremarkable X-rays
- Supports pre-read assistance
- Offers multilingual support on web and mobile
- Can be deployed on cloud or on-premise
- Provides API documentation for qXR
Use cases
- Assist radiologists with pre-reading chest X-rays
- Sort unremarkable scans to help clear reporting backlogs
- Support high-volume teleradiology reporting
- Screen chest X-rays for TB and lung cancer
- Review chest X-rays in immigration screening programs
Capabilities
Latest updates
- Qure.ai's Clinical Decision Support System Aira Among World's First to Win Class...
Clinical Decision Support System Aira among world's first to win Class...
- Qure.ai nets six new indications cleared by the FDA, taking the chest X-ray crow...
Six new indications cleared by the FDA.
- Qure.ai continues its pace of US growth with 19th FDA clearance
19th FDA clearance.
- AI tool regulatory cleared for early detection of TB in children aged 0-3 years,...
AI tool regulatory cleared for early detection of TB in children aged 0-3 years.
Where it works
Web · API
More from Qure.ai
- qER
qER analyzes head CT scans to flag suspected intracranial bleeding and other urgent findings for clinical triage.
Questions about qXR
Does qXR have an API?
Yes. The maker’s pages state that qXR has an API. Read on the maker’s pages on 18 Nov 2026.
Which platforms does qXR run on?
qXR runs on Web and API, as its maker’s pages state. Read on the maker’s pages on 18 Nov 2026.
Is qXR still available?
Yes, as of 18 Nov 2026: its maker’s pages were read that day and carried no notice that qXR has ended.
What changed recently in qXR?
The latest entry in its maker’s changelog: 17 Sept 2026, “Qure.ai's Clinical Decision Support System Aira Among World's First to Win Class...”. Before it: 26 Feb 2026, “Qure.ai nets six new indications cleared by the FDA, taking the chest X-ray crow...”. Changelog checked on 18 Nov 2026.
Sources
- https://www.qure.ai/product/qxr — Product capabilities, intended audiences, deployment options and demo request.
- https://documentation.qure.ai/api/platform-api/get-started/qxr — Official qXR API documentation.
- https://www.qure.ai/us/news-press-coverages/qure.ai-nets-six-new-indications-cleared-by-the-fda-taking-the-chest-x-ray-crown-in-the-radiology-ai-race — Qure.ai announcement dated 2026-02-26 about qXR-Detect indications.
- https://www.qure.ai/us/blog — Official blog search; its listed posts were not a more recent qXR product change.
Not confirmed
- Prices
- Search for an official qXR pricing page did not locate one.
- No official pricing page was available to read.
- No official pricing page was available to verify tiers or prices.
- No official tier or price was published on the pages accessed.
- Free plan
- The official pages accessed did not confirm whether a free tier exists.
- Latest version
- No current qXR version or model name was shown on the official pages accessed.
- Open source
- The official pages accessed did not state a license or open-source status.